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Summary This study examines the expression of MHC class I and II antigens and their related invariant
chains in 70 cases of human hepatocellular carcinoma (HCC), using monoclonal (Mabs) and polyclonal
antibodies. In comparison with normal hepatocytes, the majority (94.3%) of HCCs show enhancement or
acquisition of HLA-A, B, C in either a cytoplasmic or membranous distribu'tion, with staining being uni-
formly distributed throughout the specimen. HLA-A, B, C was accompanied by fl,-microglobulin expression
in all but two cases. Although 44.9% of specimens showed HLA-DR expression, positively staining tumour
cells were often sparse and heterogeneously distributed. By contrast, the invariant (I) chain, present in 47.1%
of cases, was frequently intensively stained and extensive in distribution. HLA-DR staining was usually
cytoplasmic although two cases showed faint membranous enhancement. In addition to HLA-DR and I-
chain, two cases also showed HLA-DQ staining. Display of MHC antigens was not related to tumour
differentiation or size of the lesion (resected vs. advanced tumours). It is possible that the acquisition of class
I antigens by the majority of HCCs may influence tumour behaviour.
Further to their role in the restriction of the immune
response in viral infection and transplantation, there is
evidence to suggest that the products of the major histo-
compatibility complex (MHC) genes may influence tumour
growth and metastasis. This relationship has been extensively
studied in vitro and in vivo using animal models (Goodenow
et al., 1985), and may also contribute to the behaviour of
certain human tumours (Fleming et al., 1981; Ruiter et al.,
1986; Doyle et al., 1985; Whelan et al., 1985; van den Ingh
et al., 1987). The mechanism(s) by which the MHC antigens
modify tumour behaviour still require clarification (Demant,
1986; Festenstein, 1987).
The class I antigens (HLA-A, -B, -C) are 45kD trans-
membrane glycoproteins noncovalently associated with a
12kD invariant light chain, fl,2-microglobulin (f2m)
(Strachan, 1987). Their distribution is more restricted than
was originally held (Daar et al., 1984). The situation
pertaining to hepatocytes is uncertain with some workers
failing to detect them on normal liver cells (Ponder et al.,
1983; Lautenschlager et al., 1984; Fukusato et al., 1986) and
others reporting their presence at low levels (Saunders et al.,
1979; Montano et al., 1982; Nagafuchi et al., 1985;
Nagafuchi & Scheuer, 1986).
Class II antigens (HLA-DP, -DQ, -DR) comprise two
noncovalently linked transmembrane polypeptides (Lafuse &
David, 1984), associated for part of the cell cycle with
another transmembranous glycoprotein, the invariant (I)
chain (Jones et al., 1978). Although their distribution is more
widespread than originally recognised, it is generally agreed
that hepatocytes do not express class II antigens in normal
liver (Fukusato et al., 1986). Both class I and class II
products may be displayed by hepatocytes under a variety of
pathological conditions, however (Nagafuchi et al., 1985;
Fukusato et al., 1986; Nagafuchi & Scheuer, 1986; van den
Oord et al., 1986).
To date there is limited information available on HLA
expression in hepatocellular carcinoma (HCC) with relatively
few examples having been examined, either as solid tumours
or cell lines (Natali 1981; Fukusato et al., 1986; Mazzeo et
al., 1986). We have therefore studied the pattern of
expression of HLA-A, -B, -C and ,B2m, as well as HLA-DQ,
HLA-DR and the associated I chain, using appropriate
monoclonal and polyclonal antibodies.
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Materials and methods
Human tissues
The series comprised 70 samples of hepatocellular carcinoma
from 56 black and 14 caucasian patients (66 male, 4 female)
Hepatitis B viral (HBV) status and serum alpha-foetoprotein
(AFP) levels were known in 60 cases.
Fresh tissue obtained at autopsy performed within 1 h of
death (32 cases), by needle biopsy (26), or during resection
of small tumours (12), was snap-frozen in OCT compound
(Ames Co., Div. of Miles Laboratories, Elkhard) and stored
at -70°C.
Histopathological diagnosis was made on routinely
processed H&E sections. Tumours were graded as well,
moderately or poorly differentiated according to the criteria
of the World Health Organization (World Health
Organization, 1978).
In view of the current uncertainty regarding the expression
of class I antigens on normal hepatocytes, 10 snap-frozen
samples of histologically normal liver were included as
control material. These were obtained from patients under
investigation for conditions other than HCC or HBV
infection.
Monoclonal antibodies
An anti-HLA class 1 Mab was obtained from Cappel
Laboratories, Cochranville PA, (working dilution 1:50). This
is a murine Mab of IgG1 class directed against the 45,000
dalton polypeptide associated with fl2m, obtained by
immunization of BALB/c mice with concavalin A-activated
T-cell blasts followed by fusion of immune spleen cells with
NS-1 myeloma cells (Cappel Product Information sheet).
Mabs recognising nonpolymorphic regions of HLA-DR
(anti-HLA-DR) and HLA-DQ (Leu-10), were obtained from
Becton-Dickinson, Sunnyvale CA; (working dilutions 1:200
and 1:50 respectively). VIC-YI is a monoclonal antibody
recognising the invariant (I) chain of HLA-DR (Quaranta et
al., 1984). Working dilution for VIC-Y1 was 1:200.
In addition, T-cell subsets were examined with a panel of
commercially available Mabs: Leu-7 detecting killer and
natural killer (NK) cells (Becton-Dickinson); OKT-4
reacting with helper/inducer T-cells (Ortho Pharmaceutical
Co., Raritan, NJ); OKT-8 against suppressor/cytotoxic T-
cells (Ortho). All were applied at a dilution of 1: 10.
c
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Polyclonal antibodies
Rabbit antibodies against the hepatitis B virus (HBV)
surface antigen (anti-HBsAg), core antigen (anti-HBcAg),
and human /2m were purchased from Dako Immuno-
globulins. They were applied for 30min at dilutions of 1:50,
1:20 and 1:200 respectively.
Immunoperoxidase techniques
Cryostat sections (5 ,um) were air-dried overnight at room
temperature, fixed for 10min in absolute acetone and stored
wrapped in aluminium foil, at -20°C until use.
Monoclonal antibodies were demonstrated by a three step
immunoperoxidase technique. Serial sections were rehydrated
in PBS (pH 7.2) and incubated with the Mabs for 30min at
the dilutions specified above. The second and third steps
comprised treatment for 30min with rabbit-antimouse
immunoglobulins (Igs) (Dako) at a dilution of 1:50, followed
by peroxidase conjugated swine-antirabbit Igs (Dako),
dilution 1:100, also for 30min. Ten percent human AB
serum was added to each, to reduce background staining.
Each step was followed by vigorous washing in PBS.
Sections were then incubated with 0.05% 3-amino-9-
ethylcarbazole in 0.05M acetate buffer (pH4.9) and 0.01%
H202. All staining was carried out at room temperature.
Polyclonal antibodies were used in a three-step unlabelled
peroxidase-antiperoxidase procedure performed at room
temperature. Sections were incubated with primary
antibodies for 30min at the dilutions specified above, This
was followed by swine-anti rabbit Igs (dilution 1:100) and,
thereafter, rabbit peroxidase-antiperoxidase complex (Dako;
dilution 1:300), both for 30min. Sections were washed in
three changes of PBS between steps. The reaction product
was developed with 3-amino-9-ethylcarbazole and H202'
Negative controls consisted of omission of the primary
antibody or use of the chromogen alone.
Slides were examined in batches according to primary
antibody to allow later comparison between MHC products
and their relevant invariant chains. Staining of HLA-A, -B,
-C and f2m was recorded as absent, cytoplasmic and
membranous (±cytoplasmic). HLA-DR, -DQ and I chain
staining were scored as 0 (absent), 1 + (<10% of
hepatocytes positively staining), 2+ (10-50% positive), 3+
(>50% positive) and 4+ (>90% of cells positive).
Results
Of 70 cases examined, 23 were well, 33 moderately and 14
poorly differentiated HCC. Twelve were resected specimens,
staged as 'early' HCC, and the remainder represented
advanced tumours. HBsAg and HBcAg were demonstrated
by immunostaining in one case.
Class I expression
In addition to sinsoidal staining (endothelial and Kupffer
cells), weak, membranous display of HLA-A, -B, -C was
observed on variable numbers of hepatocytes in all 10
histologically normal livers (Figure 1).
Positive staining for HLA-A, -B, -C was present in 66 of
70 cases (94.3%). Of the 66 positive tissues, 41 displayed
membranous staining accompanied by variable intracyto-
plasmic positivity (Figure 2), while 23 showed a granular
intracytoplasmic stain, sometimes accompanied by sinusoidal
enhancement (Figure 3). In 4 specimens the tumour was
negative for the antigen although adjacent non-neoplastic
hepatocytes showed enhanced membranous HLA-A, -B, -C
display (Figure 4). Staining was of uniform consistency in
positive specimens with the cytoplasmic or membranous
pattern being conserved throughout. In all tumours as well
as adjacent non-neoplastic hepatocytes displaying class I
Figure 1 Histologically normal liver. Intense HLA-A, B, C
staining is observed within sinusoids, while hepatocyte mem-
branes show variable faint positivity (arrowed). (Immuno-
peroxidase x 640).
Figure 2 Membranous HLA-A, B, C display in hepatocellular
carcinoma. Staining is typically uniform throughout the specimen
and is more intense than that observed on apparently normal
hepatocytes as illustrated in Figure 1. (Immunoperoxidase x 323).
Figure 3 Hepatocellular carcinoma showing diffuse cytoplasmic
staining for HLA-A, B, C. The membranous enhancement
observed in Figure 2 is absent. (Immunoperoxidase x 528).HLA EXPRESSION IN HCC 371
..
% %. w,
Figure 4 Hepatocellular carcinoma showing absence of HLA-A,
B, C staining. Non-tumorous hepatocytes (arrowed) show an
enhanced 'honeycomb' pattern of membranous positivity.
(Immunoperoxidase x 400).
antigens, staining was considerably more intense than was
observed in the control group.
f2m staining accompanied HLA-A, -B, -C in all but two
cases which were f22m negative but showed faint cytoplasmic
HLA-A, -B, -C positivity. The pattern of expression was
either cytoplasmic or membranous and generally correlated
with the heavy chain.
Class II expression
Twenty-nine cases (41.4%) were positive for HLA-DR.
Staining was invariably heterogeneous (Figure 5). In 10 of
these the extent of staining was graded as 1 +, 9 were read
as 2+, 6 as 3 +, and 4 showed 4+ positivity.
All cases positive for HLA-DR also showed VICYI
staining. In addition a further 4 cases were VICYI +/HLA-
DR-. In contrast to the relationship between HLA-A, -B, -C
and fl2m, however, I chain staining was invariably far in
excess of that observed for its associated MHC product
(Figure 6). Thus, of 33 cases (47.1%) staining with VICY1, 4
were graded as 1+, 5 as 2+, 10 as 3+, and 14 showed 4+
positivity.
For both Mabs, staining tended to be heterogenous, with
Figure 5 Hepatocellular carcinoma stained for HLA-DR.
Display of the antigen is sparse (arrowed). Note the apical
cytoplasmic stain in the pseudoglandular areas, one containing a
central bile plug (asterisk). (Immunoperoxidase x 400).
Figure 6 Serial section for comparison with Figure 5. Intense
and extensive staining of I chain with the Mab VICYI.
(Immunoperoxidase x400).
staining intensity varying from cell to cell. In tumours
showing a pseudoglandular pattern the HLA-DR positivity
was often confined to the apical portion of the cell (Figure
5). Both antigens tended to be intracytoplasmic although in
two tumours occasional small foci of membranous HLA-DR
expression were noted.
Two cases stained for HLA-DQ in addition to HLA-DR
and I chain. Staining was less intense and more focal than
was observed for HLA-DR on serial sections.
All tumours showed a mild to moderate T-cell infiltrate,
with OKT-4+ cells (helper/inducer T-cells) being slightly in
excess of OKT-8+ cells (cytotoxic/suppressor T-cells). T-cells
were usually confined to intervening stroma and at the
margins of resected lesions. There was little infiltration
between tumour cells, and NK cells were extremely scarce in
all specimens. No relationship between inflammatory
infiltrate and MHC status was demonstrated although in two
cases there was enhanced HLA-DR and I chain staining in a
periseptal distribution and around clusters of helper/inducer
T-cells.
No relationship was observed between expression of class I
or class II antigens and tumour differentiation, stage or
HBV status (data not shown).
Discussion
In this study we have examined the patterns of MHC class I
and II display in hepatocellular carcinoma. We have also
attempted to qualify the relationship between these antigens
and their respective invariant chains.
Expression of class I antigens by normal hepatocytes
remains controversial. In our series of non-tumorous biopsies
there was faint membranous expression of class I antigens by
some liver cells. However such expression may represent a
facile response of the hepatocyte to a variety of stimuli
(Nagafuchi et al., 1985; Fukusato et al., 1986). Biopsies read
as histologically normal in this and other studies, and which
express HLA-A, -B, -C, may not represent 'normal' liver,
with unrecognised immunological factors or agents such as
drugs or alcohol promoting the expression of HLA products
at the hepatocyte membrane. This may explain the variable
findings in the different series reported to date (Saunders et
al., 1979; Montano et al., 1982; Ponder et al., 1983;
Lautenschlager et al., 1984; Nagafuchi et al., 1985; Fukusato
et al., 1986; Nagafuchi & Scheuer, 1986). However, if HLA-
A, -B, -C is expressed at all on normal liver cells then it
would appear to be at very low levels.
I
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Our results suggest, therefore, that malignant trans-
formation of hepatocytes is characterized by expression of
class I antigens that is at least enhanced if not acquired de
novo, with virtually all tumours in this series showing intense
staining for class I antigens. This finding is in keeping with
observations reported elsewhere for small series of HCC
(Fukusato et al., 1986; Mazzeo et al., 1986).
This contrasts with the situation reported for other human
tumours, including colorectal carcinomas in which there is
sometimes loss of expression in comparison with the non-
neoplastic epithelium (Daar et al., 1982; Csiba et al., 1984;
Momburg et al., 1986; van den Ingh et al., 1987).
Furthermore it is suggested by some investigators that loss
of display is related to progressive de-differentiation and
prognosis (Momburg et al., 1986; van den Ingh et al., 1987).
This observation has also been made for malignant
melanomas in which attenuated or absent class I expression
is associated with a high degree of malignancy (Ruiter et al.,
1986). We have not observed any relationship between MHC
expression and tumour differentiation in HCC.
Class II antigens were expressed in nearly half of the cases
in our series. Expression was heterogeneous and often rather
sparce, however, and was always associated with VICY1
positivity, although the latter typically showed far more
extensive and intense staining than HLA-DR.
The Mab VICYI is directed at the core protein of the
class II-associated I chain proteoglycan (Giacoletto et al.,
1986). It is an unusual transmembranous glycoprotein with
some structural similarity to certain membrane receptor
molecules including the transferrin receptor (Creswell et al.,
1987). Its function at this time is unknown although it may
participate in one or more of a variety of activities:
biosynthesis, transport/recycling, immune mediation or other
as yet unrecognised functions (Koch & Harris, 1984; Long,
1985; Giacoletto et al., 1986; Creswell et al., 1987). Although
some cases in our series expressed the I chain in the absence
of HLA-DR, it may be that this represents tissue selection
rather than true absence of HLA-DR, as the class II antigen
is expressed extremely sparcely in some cases showing strong
VICYI staining. It is noted, however, that the murine
equivalent of the I chain has been demonstrated in the
absence of class II antigen in B-lymphoid and myeloid cell
lines (Koch & Harris, 1984), and a subset of tumour cells in
one case of mediastinal B-cell lymphoma has been reported
to be positive for I chain in the absence of HLA-DR and
-DQ (M6ller et al., 1986). Furthermore, hyperexpression of
the I chain has been demonstrated by electrophoretic
techniques in Epstein-Barr virus-transformed leukaemic cells
(Spiro et al., 1985). To our knowledge the VICYI antibody
has not previously been applied to epithelial neoplasms, and
our observations suggest that it may be of value in the study
of class II expression in other tumours.
Although HLA-DR expression has been observed in
reactive hepatocytes during HBV infection (Fachetti et al.,
1985; van den Oord et al., 1986), data for HLA-DQ
expression are not available. We believe that the expression
of HLA-DQ in some tumours in this series implies that non-
neoplastic liver cells may also express this antigen, but in a
sequential or dissociated fashion (Sollid et al., 1987).
It has been suggested that the ability to display class II
antigens in response to appropriate stimuli may be
constitutive to all cells and that it is the failure to express the
antigen by a percentage of tumours which represents the
'aberrant' state (Moore & Ghosh, 1987). The observation in
two cases that both HLA-DR and I chain staining are
enhanced in a periseptal distribution may support this,
lymphokines from the adjacent lymphocytic infiltrate being
responsible for the enhancement. Conversely, no such
accentuation of staining could be demonstrated for the class
I antigens and the regular and diffuse nature of antigen
expression in all but a minority of cases suggests to us that it
represents a constitutive component in malignant trans-
formation of hepatocytes. Whether the lack of display in
some tumours represents a pre- or post-translational event is
not known.
The MHC antigens function primarily at the cell surface.
In a significant minority of malignant hepatocytes expressing
HLA-A, -B, -C, and in the vast majority displaying HLA-
DR, expression is confined to the cytoplasm. This has also
been observed with respect to class I antigens in other
tumour systems (Lampert et al., 1985; Kadin, 1980). The
effect of this distribution on functional integrity is unknown.
Just as carinogenesis is accepted to be multifactorial in
origin, so it is evident that subsequent tumour growth and
metastasis is the consequence of numerous complex factors
including characteristics of the tumour cell and host-tumour
interactions. The host's immune response to the neoplastic
cell is one such factor and any modification of the tumour
that will enable it to escape immune surveillance could
contribute to subsequent growth and metastasis. The
possibility that such modification could affect metastatic
behaviour has formed the basis of many paradigms involving
viral, chemical, or radiation induced cell transformation or
neoplasia in culture systems and/or animal models
(Goodenow et al., 1985). There is enhancement of metastatic
potential in tumours showing loss or attenuation of class I
antigens (Schrier et al., 1983), this being reversible by
transfection with the appropriate class I gene (Tanaka et al.,
1985). Furthermore, modified class I antigens may
themselves act as tumour-specific antigens (Philipps et al.,
1986), or influence tumour behaviour by interaction with
non-MHC genes or by an hormonal effect (Demant, 1986).
MHC expression and tumour behaviour may also be
related in some human tumours, including colorectal
carcinomas (van den Ingh et al., 1987), melanomas (Ruiter et
al., 1986), breast carcinomas (Fleming et al., 1981), small cell
carcinoma of lung (Doyle et al., 1985), and neuroblastomas
(Whelan et al., 1985). The possibility that this relationship
may influence the behaviour of HCC merits some con-
sideration.
HCC is a tumour associated with a uniformly fatal
outcome unless detected and resected at an early stage (Kew
& Geddes, 1984; Okuda, 1986). Although progress from the
time of diagnosis to death is typically rapid (Kew & Geddes,
1984), there is a prolonged subclinical period (Sheu et al.,
1985) and the tumour shows an early and sustained
proclivity for capsular and blood vessel infiltration (Wakasa
et al., 1985; Kew & Paterson, 1985).
Advanced HCCs are typically massive and show extensive
vascular infiltration and intrahepatic spread. Despite this,
metastases are often confined to clinically insignificant hilar
lymph node and pulmonary deposits (Anthony, 1978; Kew &
Paterson, 1985), with death resulting from hepatic failure or
complications of an associated cirrhosis.
While many other factors may contribute to the metastatic
potential of HCC, the possibility that class I expression in
the majority of HCCs may restrict extensive extrahepatic
tumour spread should be further investigated by the
examination of defined intra- and extrahepatic metastases
and comparison with the primary lesion.
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